Steven Horn, MD
Cardiovascular Disease · Amherst, NYNPI 1457324469
Payments from drug & device makers
Across 200 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$339
- Astellas Pharma US Inc$286
- Biotronik Inc.$268
- E.r. Squibb & Sons, L.L.C.$266
- Cvrx, Inc.$266
- Johnson & Johnson$253
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,98596%
- Education$1794%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 21 | $339 |
| Astellas Pharma US Inc | 8 | $286 |
| Biotronik Inc. | 8 | $268 |
| E.r. Squibb & Sons, L.L.C. | 22 | $266 |
| Cvrx, Inc. | 11 | $266 |
| Johnson & Johnson | 14 | $253 |
| Abbott | 12 | $245 |
| Novartis | 15 | $224 |
| Boston Scientific | 7 | $218 |
| Pfizer | 14 | $218 |
| Medtronic(2 entities) | 4 | $185 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $164 |
| Inspire Medical Systems, Inc. | 2 | $151 |
| Sanofi-aventis U.S. LLC | 8 | $147 |
| Edwards Lifesciences | 6 | $132 |
| Kestra Medical Technology Services, Inc. | 3 | $94 |
| Impulse Dynamics (USA) Inc. | 2 | $75 |
| Amarin Pharma, Inc. | 5 | $71 |
| Alnylam Pharmaceuticals Inc. | 3 | $68 |
| AstraZeneca | 4 | $62 |
| Irhythm Technologies, Inc. | 2 | $61 |
| Baxter Healthcare | 1 | $58 |
| Merck | 3 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $34 |
| Bridgebio Pharma, Inc. | 2 | $29 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Tactile Systems Technology Inc | 1 | $24 |
| Boehringer Ingelheim | 1 | $24 |
| Daiichi Sankyo Inc. | 2 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Gilead | 1 | $15 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$127
How this compares
$4,164 in reported general payments places this provider in the 65th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 964 | $1,263,756 |
| XareltoRivaroxaban | 223 | $290,612 |
| EntrestoSacubitril/Valsartan | 119 | $166,929 |
| Repatha SureclickEvolocumab | 93 | $120,014 |
| JardianceEmpagliflozin | 45 | $56,398 |
| FarxigaDapagliflozin Propanediol | 29 | $40,501 |
| Metoprolol Succinate | 937 | $21,504 |
| Praluent PenAlirocumab | 21 | $18,353 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 26 | $14,063 |
| Rosuvastatin Calcium | 480 | $8,720 |
| Atorvastatin Calcium | 350 | $6,278 |
| Ezetimibe | 224 | $5,777 |
| Pitavastatin Calcium | 15 | $5,484 |
| Ranolazine ErRanolazine | 39 | $5,095 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 128 | $5,050 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $218 | $1,263,756964 claims |
| Johnson & JohnsonXarelto | $253 | $290,612223 claims |
| NovartisEntresto | $224 | $166,929119 claims |
| Boehringer IngelheimJardiance | $24 | $56,39845 claims |
| AstraZenecaFarxiga | $62 | $40,50129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Amherst
- Vijay IyerAmherst$4.3M
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
- Sean DonahoeRiverhead$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.